LeonaBio presents clinical strategy for ALS candidate brelgometon
LeonaBio (NASDAQ:LONA) announced today that Chief Medical Officer Javier San Martin, MD, presented the company’s clinical strategy for its lead ALS candidate, brelgometon (ATH-1105), at the 5th Annual ALS Drug Development Summit in Boston.










